1.
Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)
by Woodward, Mark
Heart (British Cardiac Society), 2007, Vol.93 (2), p.172-176

2.
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
by Muntner, Paul, PhD
The American heart journal, 2011, Vol.161 (4), p.719-725

3.
Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fl...
by Fayad, Zahi A., PhD
The American heart journal, 2011, Vol.162 (2), p.214-221.e2

4.
Combined Role of Reduced Estimated Glomerular Filtration Rate and Microalbuminuria on the Prevalence of Peripheral Arterial Disease
by Baber, Usman, MD
The American journal of cardiology, 2009, Vol.104 (10), p.1446-1451

5.
Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease:...
by Chalmers, John
Hypertension (Dallas, Tex. 1979), 2014, Vol.63 (2), p.259-264

6.
Effects of Prehypertension and Hypertension Subtype on Cardiovascular Disease in the Asia-Pacific Region
by Arima, Hisatomi
Hypertension (Dallas, Tex. 1979), 2012, Vol.59 (6), p.1118-1123

7.
Blood Pressure Indices and Cardiovascular Disease in the Asia Pacific Region: A Pooled Analysis
by Lawes, Carlene M M
Hypertension (Dallas, Tex. 1979), 2003, Vol.42 (1), p.69-75

8.
The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition
by HARRAP, Stephen B
Hypertension (Dallas, Tex. 1979), 2003, Vol.42 (3), p.297-303

9.
Impact of Blood Pressure Lowering on Cardiovascular Outcomes in Normal Weight, Overweight, and Obese Individuals: The Perindopril Protection Against Recurrent Stroke Study Trial
by Czernichow, Sébastien
Hypertension (Dallas, Tex. 1979), 2010, Vol.55 (5), p.1193-1198
